12 hours ago
1
Three patient deaths linked to neuromuscular drugs developed by Sarepta Therapeutics (NASDAQ:SRPT) have drawn regulatory scrutiny on the viral vector used in the company’s gene therapy platform technology.
The Cambridge, Massachusetts-based biotech has lost over $10B of its value, or more than 90% of
English (US) ·